NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Safety and Efficacy of Trastuzumab BS

NCT04181333

CompletedN/A

Sponsor: Pfizer

Conditions: Gastric Cancer

Interventions: TRASTUZUMAB BS

Countries: Japan

To confirm the safety and efficacy of this drug under the actual use

Eligibility overview

Sex: ALL

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with unresectable advanced/recurrent gastric cancer who are confirmed to have HER2 overexpression and started treatment with this drug\*
* Patients who receive this drug\* for the first time after this drug\* is launched \* Not including the biological product, HERCEPTIN, and biosimilars of HERCEPTIN other than this drug

Exclusion Criteria:

\- not specified in this study

Locations (1)

Tokyo, Japan